News
EQ
0.7549
-3.22%
-0.0251
Weekly Report: what happened at EQ last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at EQ last week (0224-0228)?
Weekly Report · 03/03 11:47
Weekly Report: what happened at EQ last week (0217-0221)?
Weekly Report · 02/24 11:47
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
NASDAQ · 02/21 14:55
Weekly Report: what happened at EQ last week (0210-0214)?
Weekly Report · 02/17 11:44
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Zoetis (ZTS) and Encompass Health (EHC)
TipRanks · 02/11 06:50
Weekly Report: what happened at EQ last week (0203-0207)?
Weekly Report · 02/10 11:37
After Hours Most Active for Feb 7, 2025 : MRP, IP, INTC, F, CSCO, GRAB, COP, GOOGL, NVDA, AMZN, HIMS, EQT
NASDAQ · 02/07 21:24
Equillium stock rallies 26% on itolizumab study data
Seeking Alpha · 02/06 18:22
Equillium announces itolizumab study achieves secondary endpoint
TipRanks · 02/06 13:30
EQUILLIUM ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY EVALUATING ITOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Reuters · 02/06 13:00
EQUILLIUM INC - ITOLIZUMAB ACHIEVES 16.7% ENDOSCOPIC REMISSION IN PHASE 2 STUDY
Reuters · 02/06 13:00
Weekly Report: what happened at EQ last week (0127-0131)?
Weekly Report · 02/03 11:42
Weekly Report: what happened at EQ last week (0120-0124)?
Weekly Report · 01/27 11:46
Weekly Report: what happened at EQ last week (0113-0117)?
Weekly Report · 01/20 11:36
Weekly Report: what happened at EQ last week (0106-0110)?
Weekly Report · 01/13 11:37
Weekly Report: what happened at EQ last week (1230-0103)?
Weekly Report · 01/06 11:46
Weekly Report: what happened at EQ last week (1223-1227)?
Weekly Report · 12/30/2024 11:39
Weekly Report: what happened at EQ last week (1216-1220)?
Weekly Report · 12/23/2024 11:47
Weekly Report: what happened at EQ last week (1209-1213)?
Weekly Report · 12/16/2024 11:48
More
Webull provides a variety of real-time EQ stock news. You can receive the latest news about Equillium through multiple platforms. This information may help you make smarter investment decisions.
About EQ
More
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.